ThermoGenesis Announces National Institute of He...( COMPANY'S FIRST-EVER NIH GRANT WILL B...),Health

COMPANY'S FIRST-EVER NIH GRANT WILL BE USED TO DEVELOP CELL DELIVERY TECHNOLOGIES FOR REGENERATIVE MEDICINE APPLICATIONS

RANCHO CORDOVA, Calif., June 9 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, said today it has received a grant from the National Institute of Health (NIH) to study and develop biomaterials that can be used to deploy placental stem cells in bone repair and regenerative medicine applications.

The approximate $500,000, two-year grant, the Company's first-ever funding from the NIH, is a Phase I Small Business Innovation Research grant from the National Institute on Aging. The study will be conducted at the Company's stem cell research laboratory and through a collaboration with the University of California, Davis. The Company can apply for a Phase II grant once the work under this initial contract is completed.

"Being awarded this grant is an important milestone for the Company. These funds enable us to conduct exploratory research in animal models to identify the best methods of combining stem cells with biomaterials," noted Mel Engle, Chief Executive Officer of ThermoGenesis. "We will be using stem cell concentrates prepared by our AXP(TM) AutoXpress (AXP(TM)), MarrowXpress(TM) (MXP) and Res-Q(TM) cell separation technologies as well as cells derived from the placenta. The goal of this research is to provide an integrated cell processing and delivery system designed to achieve an optimal therapeutic effect in orthopedic applications, such as bone repair and generation." Engle said the Company's research is based upon the growing body of evidence which shows that the efficacy of stem cells for tissue regeneration and repair can be enhanced if the cells are presented to the body wi
'/>"/>